학술논문
Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
Document Type
Article
Author
Source
In Cell Reports Medicine 20 September 2022 3(9)
Subject
Language
ISSN
2666-3791